Advertisement


Ken Kato, MD, PhD, on Advanced Esophageal Cancer: Biomarker Analyses From CheckMate 648

2024 ASCO GI Cancers Symposium

Advertisement

Ken Kato, MD, PhD, of Japan’s National Cancer Center Hospital, discusses the first comprehensive findings on biomarkers from the CheckMate 648 study. These results further corroborate the clinical efficacy of nivolumab plus chemotherapy and nivolumab plus ipilimumab in the first-line treatment of advanced esophageal squamous cell carcinoma. According to Dr. Kato, the data suggest an overall survival benefit across multiple biomarker subgroups (Abstract 252).



Related Videos

Colorectal Cancer

Dominik P. Modest, MD, on Colorectal Cancer: Health-Related Quality-of-Life Findings From CodeBreaK 300

Dominik P. Modest, MD, of Charité-Universitätsmedizin Berlin, discusses phase III study findings showing sotorasib plus panitumumab vs trifluridine/tipiracil or regorafenib benefits patients with chemorefractory metastatic colorectal cancer in terms of improved clinical outcomes and better self-reported quality of life (Abstract 10).

Gastroesophageal Cancer
Gastrointestinal Cancer

Ian Chau, MD, on Gastrointestinal Cancers: Real-World Effectiveness of Nivolumab Plus Chemotherapy

Ian Chau, MD, of The Royal Marsden Hospital, discusses reportedly the first study to evaluate the real-world effectiveness of nivolumab as a first-line treatment of advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma. The combination therapy improved overall survival compared with chemotherapy alone. Dr. Chau presents the 18-month follow-up results (Abstract 295).

Gastrointestinal Cancer
Immunotherapy

Yasunobu Ishizuka, MD, on Gastric Cancer: Does Nivolumab Infusion Time of Day Matter?

Yasunobu Ishizuka, MD, of Japan’s Aichi Cancer Center, discusses study results showing that scheduling infusions of nivolumab monotherapy before mid-afternoon for patients with metastatic gastric cancer may alter treatment efficacy. Several studies have suggested that circadian rhythm is essential in immune system function, including anticancer immunity (Abstract 268).

Gastroesophageal Cancer
Gastrointestinal Cancer

Anant Ramaswamy, DM, on Advanced Gastric Cancers: New Findings on Adding Docetaxel to Doublet

Anant Ramaswamy, DM, of Tata Memorial Centre, discusses phase III results of a study that added docetaxel to a doublet regimen of fluorouracil or capecitabine and oxaliplatin, which did not improve overall survival in patients with advanced gastroesophageal junction and gastric cancers. Continuing chemotherapy beyond 6 months also did not appear to improve survival in this population (Abstract LBA248).

Gastroesophageal Cancer

Michael K. Gibson, MD, PhD, on Esophageal Cancer: Expert Commentary on Two Key Studies

Michael K. Gibson, MD, PhD, of Vanderbilt University Medical Center, discusses phase III findings on chemotherapy plus camrelizumab in the ESCORT-NEO trial of patients with resectable esophageal squamous cell carcinoma; and phase III SKYSCRAPER-08 results on first-line tiragolumab plus atezolizumab and chemotherapy in the same patient population (Abstracts LBA244 and 245).

Advertisement

Advertisement




Advertisement